朱校，男，復旦大學藥學院青年研究員，博士生導師，碩士生導師，入選上海“高校青年英才攬蓄工程”。博士畢業於紐西蘭奧塔哥大學藥學院，研究領域為群體藥代動力學藥效學和定量系統藥理學，師從本領域著名專家Stephen Duffull教授。已主持國家自然科學基金等各類基金項目3項，榮獲2019年度國家優秀自費留學生獎和2019年大洋洲臨床和實驗藥理學家毒理學家學會Fred Fastier獎，曾在2019年歐洲定量藥理學年會(PAGE)的Stuart Beal方法學專題做大會報告。以第一作者/通訊作者在Adv. Sci., Br. J. Pharmacol.(4篇), J. Antimicrob. Chemother., Antimicrob. Agents Chemother.等國際權威期刊發表高水平科研論文20餘篇，並參與多項CDE指導原則的編寫。現為中國藥理學會定量藥理專委會委員，中國藥理學會臨床藥理專委會青年委員，中國藥理學會藥物代謝專委會青年委員，上海藥理學會臨床藥理專委會委員，上海藥理學會藥物代謝專委會委員，DIA中國臨床藥理工作組南組組長。任《群體藥動學和藥效學分析進階》一書副主編。
基本介紹
- 中文名：朱校
- 國籍：中國
- 民族：漢族
- 學位/學歷：博士
- 專業方向：群體藥代動力學藥效學和定量系統藥理學
- 職務：青年研究員，博士生導師，碩士生導師
個人簡介,研究方向,教育經歷,工作經歷,科研項目,學術兼職,榮譽獎勵,代表論著,
個人簡介
復旦大學藥學院青年研究員PI，博士生導師，入選上海“高校青年英才攬蓄工程”。博士畢業於紐西蘭奧塔哥大學藥學院，研究領域為群體藥代動力學藥效學和定量系統藥理學，師從本領域著名專家Stephen Duffull教授。已主持國家自然科學基金等各類基金項目3項，榮獲2019年度國家優秀自費留學生獎和2019年大洋洲臨床和實驗藥理學家毒理學家學會Fred Fastier獎，曾在2019年歐洲定量藥理學年會(PAGE)的Stuart Beal方法學專題做大會報告。以第一作者/通訊作者在Adv. Sci., Br. J. Pharmacol.(4篇), J. Antimicrob. Chemother., Antimicrob. Agents Chemother.等國際權威期刊發表高水平科研論文20餘篇，並參與多項CDE指導原則的編寫。現為中國藥理學會定量藥理專委會委員，中國藥理學會臨床藥理專委會青年委員，中國藥理學會藥物代謝專委會青年委員，上海藥理學會臨床藥理專委會委員，上海藥理學會藥物代謝專委會委員，DIA中國臨床藥理工作組南組組長。任《群體藥動學和藥效學分析進階》一書副主編。
研究方向
聚焦於定量藥理學領域，旨在通過數理統計方法整合提煉藥物全生命周期的信息，助力新藥創製和臨床精準用藥。具體研究方向包括：
（1）群體藥代動力學和藥效學
（2）定量系統藥理學
（3）受體理論
教育經歷
奧塔哥大學
2016/03 – 2019/05 定量藥理學博士
導師: Stephen Duffull教授, Michelle Glass教授
香港中文大學
2012/08 – 2015/09 藥學碩士
導師: Lam Tai-ning教授, 左中教授
北京大學/輝瑞定量藥理學教學中心
2015/02 – 2015/07 交換生
導師: 盧煒教授, 周田彥教授
復旦大學
2008/09 – 2012/07 藥學理學學士
工作經歷
2021/07 至 今 復旦大學藥學院青年研究員
2020/03 – 2021/06默多克兒童研究所Honorary Fellow
2019/11 – 2020/12奧塔哥定量藥理組Postdoctoral Fellow
導師: Stephen Duffull教授, Amanda Gwee醫生
2019/06 – 2019/10奧塔哥定量藥理組Assistant Research Fellow
2015/10 – 2016/02葛蘭素史克中國上海研發中心臨床藥理建模仿真部門實習生
導師: 馬培敏博士, 吳凱博士
科研項目
國家自然科學基金青年科學基金項目: 工程化巨噬細胞體內命運的定量藥理研究（批准號：82204544）（2023-2025，主持）
上海市衛健委衛生行業臨床研究青年項目: 利奈唑胺在中國肝移植患者中的群體藥代動力學及毒代動力學分析（批准號：20224Y0121）（2023-2025，主持）
複雜基質樣本生物分析湖南省重點實驗室開放課題：基於群體藥代動力學模型庫的兒科人群臨床試驗最佳化設計框架的建立：以卡泊芬淨為例（批准號：FZJZ-202305）(2024-2025, 主持)
復旦大學引進人才科研基金（2021-2026，主持）
學術兼職
中國藥理學會定量藥理專業委員會，委員
中國藥理學會臨床藥理專業委員會，青年委員
中國藥理學會藥物代謝專業委員會，青年委員
上海藥理學會藥物代謝專業委員會，委員
上海藥理學會臨床藥理專業委員會，委員
DIA中國臨床藥理學工作組南組組長
ISoP, PAGANZ, ASCEPT會員
榮譽獎勵
2022 復旦大學“鐘揚式教學團隊”成員
2022 上海“高校青年英才攬蓄工程”入選者
2020 國家優秀自費留學生獎學金
2019 ASCEPT New Zealand Fred Fastier Prize
2019 ASCEPT and PAGANZ Student Travel Grants
2019 International Society of Pharmacometrics (ISoP) Student Prize for pharmacometrics, PAGANZ Meeting 2019, 奧克蘭, 紐西蘭
2019 奧塔哥大學藥學院2018年度最佳科研論文
代表論著
1. Liang Yang; Xiao Zhu*; David B Finlay; Hayley Green; Michelle Glass; Stephen B Duffull; A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid receptor (CB1), British Journal of Pharmacology, 2023,
2. Chong Cao; Hang Yin; Biao Yang; Qi Yue; Guoqing Wu; Meng Gu; Yuwen Zhang; Yang Fan; Xiaoyan Dong; Ting Wang; Cong Wang; Xiao Zhu*; Ying Mao*; Xiao-Yong Zhang*; Zuhai Lei*; Cong Li*; Intra-operative Definition of Glioma Infiltrative Margins by Visualizing Immunosuppressive Tumor-Associated Macrophages, Advanced Science (Weinh), 2023; e2304020
3. Xin Liu; Gehang Ju; Xinyi Huang; Wenyu Yang; Lulu Chen; Chao Li; Qingfeng He; Nuo Xu; Xiao Zhu*; Dongsheng Ouyang*; Escitalopram population pharmacokinetics and remedial strategies based on CYP2C19 phenotype, Journal of affective disorders. 2023; 346:64-74.
4. Gaoqi Xu#; Dihong Yang#; Chaoneng He; Like Zhong; Junfeng Zhu; Qi Shu; Haiying Ding; Wenxiu Xin; Yinghui Tong; Xiao Zhu*; Luo Fang*; Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer, Cancer Chemotherapy and Pharmacology, 2023, doi:10.1007/s00280-023-04559-y
5. Wenyu Yang#; Wenyao Mak#; Amanda Gwee; Meng Gu; Yue Wu; Yufei Shi; Qingfeng He; Xiaoqiang Xiang; Bing Han*; Xiao Zhu*; Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir, Pharmaceutics, 2023, 15(7): 1801
6. Meng Gu#; An-Ning Li#; Wen-Yao Mak; Fang Dong; Nuo Xu; Jing-Ye Zhang; Yu-Fei Shi; Nan Zheng; Zhi-Jia Tang; Qing-Feng He; Can-Jun Ruan; Wei Guo; Xiao-Qiang Xiang; Chuan-Yue Wang*; Bing Han*; Xiao Zhu*; Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization, Frontiers in Pharmacology, 2023, 14:1089862
7. Anning Li #; Wen Yao Mak; Tingyi Ruan; Fang Dong; Nan Zheng; Meng Gu; Wei Guo; Jingye Zhang; Haoxuan Cheng; Canjun Ruan; Yufei Shi; Yannan Zang; Xuequan Zhu; Qingfeng He; Xiaoqiang Xiang; Gang Wang*; Xiao Zhu*; Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function. Frontiers in Pharmacology, 2023;14:1215065
8. Xin Liu; Gehang Ju; Wenyu Yang; Lulu Chen; Nuo Xu; Qingfeng He; Xiao Zhu*; Dongsheng Ouyang*; Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method. Drug Des Devel Ther. 2023;17:2955-2967
9. Amanda Gwee; Stephen B. Duffull; Andrew J. Daley; Michelle Lim; Susie Germano; Hajira Bilal; Samantha Hall; Nigel Curtis; Xiao Zhu*; Identifying a therapeutic target for vancomycin against staphylococci in young infants, The Journal of Antimicrobial Chemotherapy, 2022, 77(3): 704-710
10. Xiao Zhu#; Youyou Tao#; Ruilin Zhu*; Dezhi Wu; Wai-Kit Ming; Impact of Hospital Characteristics and Governance Structure on the Adoption of Tracking Technologies for Clinical and Supply Chain Use: Longitudinal Study of US Hospitals,Journal of Medical Internet Research,2022, 24(5): e33742
11. Xi-Wei Ji#; Xiao Zhu#; Yun Li; Feng Xue; Isabelle Hui San Kuan; Qing-Feng He; Xiang-Rui Meng; Xiao-Qiang Xiang*; Yi-Min Cui*; Bo Zheng*; Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae, Frontiers in Pharmacology, 2022, 13: 856792
12. Xiao Zhu*; David B. Finlay; Michelle Glass; Stephen B. Duffull; Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling, British Journal of Pharmacology, 2020, 177(15): 3449-3463.
13. Xiao Zhu#; David B. Finlay#; Michelle Glass*; Stephen B. Duffull*; Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors, British Journal of Pharmacology, 2019, 176(14): 2593-2607
14. Xiao Zhu*; David B. Finlay; Michelle Glass; Stephen B. Duffull; An evaluation of the operational model when applied to quantify functional selectivity, British Journal of Pharmacology, 2018, 175(10): 1654-1668
15. Xi-Wei Ji; Feng Xue; Zi-Sheng Kang; Wei Zhong; Isabelle Hui-San Kuan; Xi-Ping Yang; Xiao Zhu*; Yun Li; Yuan Lv; Model-informed drug development of benapenem: Pharmacokinetic/Pharmacodynamic cutoff value determination and antibacterial efficacy against enterobacteriaceae, Antimicrobial Agents and Chemotherapy, 2020, 64(3): e01751-19
16. Siyuan Wang#; Xiao Zhu#; Mengyi Han; Fangran Hao; Wei Lu; Tianyan Zhou*; Mechanistic Pharmacokinetic/Pharmacodynamic Model of Sunitinib and Dopamine in MCF-7/Adr Xenografts: Linking Cellular Heterogeneity to Tumour Burden,The AAPS Journal, 2020, 22(2): 45
17. Isabelle H. S. Kuan; Daniel F. B. Wright; Stephen B. Duffull; Xiao Zhu*; Understanding the association between metformin plasma concentrations and lactate, British Journal of Clinical Pharmacology, 2020,87(2): 700-701
18. Ricardo Peña-Silva; Stephen B. Duffull; Andrew C. Steer; Sandra X. Jaramillo-Rincon; Amanda Gwee; Xiao Zhu*; Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19, British Journal of Clinical Pharmacology, 2020, 87(3): 1589-1590
19. Xiao Zhu*; David B. Finlay; Michelle Glass; Stephen B. Duffull; An intact model for quantifying functional selectivity, Scientific Reports, 2019, 9(1): 2557
20. Xiao Zhu; Jianyuan Deng; Zhong Zuo; Tai Ning Lam*; An Agent-Based Approach to Dynamically Represent the Pharmacokinetic Properties of Baicalein, The AAPS Journal, 2016, 18(6): 1475-1488
21. Xi-Wei Ji; Xiang-Rui Meng; Qing-Feng He; Xiao-Qiang Xiang; Yufei Shi*; Xiao Zhu*; Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling, International Journal of Molecular Sciences, 2023, 24(1):757
22. Qiu-Yu Jia#; Qing-Feng He#; Li Yao; Min Li; Jia-Ying Lin; Zhi-Jia Tang; Xiao Zhu*; Xiao-Qiang Xiang*; Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview, Molecules, 2022,27(24):8670
其他論文
1. Amanda L Wilkins; Tony Lai; Xiao Zhu; Srinivas Bolisetty; Roberto Chiletti; Noel Cranswick; Kaya Gardiner; Rodney Hunt; Atul Malhotra; Brendan McMullan; Bhavesh Mehta; Joanna Michalowski; Himanshu Popat; Meredith Ward; Stephen Duffull; Nigel Curtis; Amanda Gwee*; Individualized vancomycin dosing in infants: prospective evaluation of an online dose calculator, International Journal of Antimicrobial Agents, 2023, 61(3): 106728.
2. Xiaowen Wang; Yiqun Yu; Hongrui Liu; Fengjiao Bu; Chunying Shen; Qingfeng He; Xiao Zhu; Pin Jiang; Bing Han*; Xiaoqiang Xiang*; Prediction of Drug-Drug Interactions with Ensartinib as a Time-Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model. Drug Metab Dispos. 2023;51(11):1515-1526
3. Chunyang Pan; Yifan Cheng; Qingfeng He; Min Li; Fengjiao Bu; Xiao Zhu; Xiaoyu Li; Xiaoqiang Xiang*; Evaluating the impact of co-administered drug and disease on ripretinib exposure: A physiologically-based pharmacokinetic modeling approach, Chemico-Biological Interactions, 2023, 373: 110400.
4. Yawen Yuan; Zhihong Li; Ke Wang; Shunguo Zhang; Qingfeng He; Lucy Liu; Zhijia Tang; Xiao Zhu; Ying Chen; Weimin Cai; Chao Peng; Xiaoqiang Xiang*; Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model, Molecules, 2023, 28(2): 837
5. Yawen Yuan; Changcheng Chen; Guoling You; Ruen Yao; Xiao Zhu; Xiaoyu Wu; Juan Wu; Wei Zhao; Zhiling Li; Shunguo Zhang*; Simultaneous quantification and pharmacokinetics of vincristine and its major metabolite M1 in Chinese pediatric ALL patients by LC-MS/MS, Journal of Pharmaceutical and Biomedical Analysis, 2023, 234: 115578
6. Zheng Liu#; Mette Julsgaard#*; Xiao Zhu; Jennifer Martin; Murray L. Barclay; Noel Cranswick; Peter R. Gibson; Richard B. Gearry; Janine van der Giessen; Susan J. Connor; Ourania Rosella; Anne Grosen; Catherine Toong; Emma Flanagan; Jantien W. Wieringa; C. Janneke van der Woude; Sally J. Bell; CARINA Study Group; Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children, Journal of Crohn's & Colitis, 2022, 16(12): 1835-1844
7. Xiwei Ji#; Xiangrui Meng#; Xiao Zhu; Qingfeng He; Yimin Cui*; Research and development of Chinese anti-COVID-19 drugs, Acta Pharmaceutica Sinica. B, 2022
8. Qingfeng He#; Fengjiao Bu#; Qizhen Wang; Min Li; Jiaying Lin; Zhijia Tang; Wen Yao Mak; Xiaomei Zhuang; Xiao Zhu; Hai-shu Lin*; Xiaoqiang Xiang*; Examination of the Impact of CYP3A4/5 on Drug–Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach, International Journal of Molecular Sciences, 2022, 23(9): 4485
9. Yawen Yuan#; Qingfeng He#; Shunguo Zhang; Min Li; Zhijia Tang; Xiao Zhu; Zheng Jiao; Weimin Cai*; Xiaoqiang Xiang*; Application of Physiologically-based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs, Frontiers in Pharmacology, 2022, 13: 895556
10.Zhipin Jin#; Qingfeng He#; Xiao Zhu; Mingshe Zhu; Yike Wang; Xin-an Wu; Qianzhou Lv*; Xiaoqiang Xiang*; Application of physiologically based pharmacokinetic modelling for the prediction of drug–drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes, Basic & Clinical Pharmacology & Toxicology, 2022, 130(5): 592-605
11.Zhen Feng; Xiaoye Li; Wai Kei Tong; Qingfeng He; Xiao Zhu; Xiaoqiang Xiang; Zhijia Tang*; Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS,Frontiers in Pharmacology, 2022; 13: 894685
12.Jinxin Zhao; Xiao Zhu; Songwen Tan*; Chuanpin Chen*; Amal Kaddoumi*; Xiu-Li Guo*; Yu-Wei Lin*; S Y Amy Cheung*; Editorial: Model-informed drug development and evidence-based translational pharmacology, Frontiers in Pharmacology, 2022; 13: 1086551
13.Jiaying Lin; Min Li; Wenyao Mak; Yufei Shi; Xiao Zhu; Zhijia Tang; Qingfeng He; Xiaoqiang Xiang; Applications of In Silico Models to Predict Drug-Induced Liver Injury, Toxics, 2022;10(12):788
14.Min Li#; Qingfeng He#; Li Yao; Xiaofeng Wang; Zhijia Tang; Xiao Zhu; Hai-Shu Lin*; Xiaoqiang Xiang*; Simultaneous Quantification of Propylthiouracil and Its N-β-d Glucuronide by HPLC-MS/MS: Application to a Metabolic Study, Pharmaceuticals, 2021, 14(11): 1194
15.Liang Yang*; Xiao Zhu; David B. Finlay; Michelle Glass; Stephen B. Duffull; Exploring group size for statistical analysis of real-time signalling experiments, British Journal of Pharmacology, 2021, 178(19):3997-4004
16.Xiao-Qin Liu#; Yi-Wei Yin#; Chen-Yu Wang; Zi-Ran Li; Xiao Zhu; Zheng Jiao*; How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing, Expert Review of Clinical Pharmacology, 2021, 14(9): 1153-1163
17.Courtney Brusamarello; Andrew J. Daley; Xiao Zhu; Cornelia Landersdorfer; Amanda Gwee*; How important are MIC determination methods when targeting vancomycin levels in patients with Staphylococcus aureus infections? The Journal of Antimicrobial Chemotherapy,2021, 76(6): 1641-1643
18.Zi-Ran Li; Chen-Yu Wang; Xiao Zhu; Zheng Jiao*; Population Pharmacokinetics of Levetiracetam: A Systematic Review, Clinical Pharmacokinetics, 2021, 60(3): 305-318
19.Amanda Gwee*; Stephen Duffull; Xiao Zhu; Steven Y. C. Tong; Noel Cranswick; Brett McWhinney; Jacobus Ungerer; Joshua Francis; Andrew C. Steer; Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children, PLoS Neglected Tropical Diseases, 2020, 14(12): e0008886
20.Liang Yang; Ling Yong; Xiao Zhu; Yaoyao Feng; Yu Fu; Daming Kong; Wei Lu; Tian-Yan Zhou*; Disease progression model of 4T1 metastatic breast cancer. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47(1): 105-116
21.Zheng Liu*; Peter Galettis; Samantha J. Broyd; Hendrika van Hell; Lisa-Marie Greenwood; Peter de Krey; Amy Steigler; Xiao Zhu; Jennifer Schneider; Nadia Solowij; Jennifer H. Martin; Model-based analysis on systemic availability of coadministered cannabinoids after controlled vaporised administration, Internal Medicine Journal,2019, 50(7): 846-853
22.Xi-Wei Ji#; Shuang-Min Ji#; Xiao-Rong He; Xiao Zhu; Rong Chen; Wei Lu*; Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. Acta Pharmacologica Sinica, 2018, 39(2): 286-293
23.Jianyuan Deng; Anika Jhandey; Xiao Zhu; Zhibo Yang; Kin Fu Patrick Yik; Zhong Zuo; Tai Ning Lam*; In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption, PloS One, 2018, 13(8): e0203361
24.Yu-Si Chen#; Zi-Qi Liu#; Rong Chen; Lei Wang; Ling Huang; Xiao Zhu; Tian-Yan Zhou; Wei Lu*; Ping Ma*; Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients, Acta Pharmacologica Sinica, 2017, 38(8): 1195-1204
25.Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam*; A Review of Food-Drug Interactions on Oral Drug Absorption, Drugs, 2017, 77(17): 1833-1855
26.Fangran Hao; Siyuan Wang; Xiao Zhu; Junsheng Xue; Jingyun Li; Lijie Wang; Jian Li; Wei Lu; Tianyan Zhou*; Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft, Pharmaceutical Research, 2017, 34(2): 408-418
27.Xi-Wei Ji#; Shuang-Min Ji#; Run-Tao Li; Ke-Hua Wu; Xiao Zhu; Wei Lu*; Tian-Yan Zhou*; Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice, Acta Pharmacologica Sinica, 2016, 37(6): 825-833
28.Lu Wang; Xiao Zhu; Cheng Xie; Ning Ding; Xiaofu Weng; Weiyue Lu; Xunbin Wei*; Cong Li*; Imaging acidosis in tumors using a pH-activated near-infrared fluorescence probe,Chemical Communications,2012, 48(95): 11677-11679
29.Yile Chen; Xiao Zhu; Yingjia Yu*; Yi Cai; Yan Li; Gengli Duan; Comparison of infrared-assisted extraction and other techniques for analysis of indigo and indirubin in leaves of isatis indigotica fort, Journal of Liquid Chromatography & Related Technologies,2012, 35(3): 362-374
30.季雙敏; 朱校; 高柳村; 楊煥; 高晨燕; 靶介導的藥物處置模型研究進展, 中國臨床藥理學與治療學, 2018, 23(5): 481-487
31.季雙敏; 朱校*; 靶點介導的藥物處置模型在單克隆抗體藥物研發中套用的探討, 中國臨床藥理學與治療學, 2018, 23(3): 241-246
學術報告
1. 報告題目：定量藥理學在兒科抗感染精準用藥中的套用。會議名稱：2023年中國藥理學會臨床藥理專業委員會青年創新論壇，濟南，中國
2. 報告題目：Use of Pharmacokinetic and Pharmacodynamic Analysis in Drug Discovery。會議名稱：ASCEPT Annual Scientific Meeting，悉尼，澳大利亞
3. 報告題目：Deciphering the Complex DMPK Behavior of CNS Drug SIPI6398 Via Model-Based Approach。會議名稱：2023 ISQP會議，上海，中國
4. 報告題目：轉化PK/PD助力雙特異性抗體的臨床開發。會議名稱：2023 DIA中國年會，蘇州，中國
5. 報告題目：模型引導的新藥研發。會議名稱：2023中國醫學前沿大會，北京，中國
6. 報告題目：時間-事件分析在嬰幼兒葡萄球菌感染治療靶標確定中的套用。會議名稱：2022首屆西部定量藥理青年論壇，成都，中國
7. 報告題目：Last-mile delivery: a reference plot to help non-pharmacometrician interpret population pharmacokinetics results。會議名稱：ISQP 2021, 北京，中國
8. 報告題目：Determination of the pharmacodynamics of vancomycin in young infants via time-to-event analysis。會議名稱：PAGANZ Virtual Meeting 2021, 悉尼, 澳大利亞
9. 報告題目：An evaluation of timed snapshot signalling bias analyses for nonequilibrium systems。會議名稱：ASCEPT-PAGANZ 2019 Joint Scientific Meeting, 皇后鎮, 紐西蘭
10. 報告題目：A cohesive model framework of receptor pharmacology: beyond the Emax model。會議名稱：Population Approach Group in Europe (PAGE) 2019, 斯德哥爾摩, 瑞典
11. 報告題目：Evaluation of the fingerprint profiles of the cannabinoid-1 receptor signalling via a kinetic modelling approach。PAGANZ Meeting 2019, 奧克蘭, 紐西蘭
12. 報告題目：A kinetic model for describing signalling profiles of the cannabinoid-1 receptor. 會議名稱：ASCEPT NZ Meeting 2018, 皇后鎮, 紐西蘭
13. 報告題目：Kinetic modelling of ligand mediated internalisation。會議名稱：PAGANZ Meeting 2018, 墨爾本, 澳大利亞
14. 報告題目：An intact model framework for quantifying functional selectivity。會議名稱： ASCEPT NZ Meeting 2017, 皇后鎮, 紐西蘭
15. 報告題目：Identifiability analysis of empirical models used for quantifying “biased” ligands。會議名稱：PAGANZ Meeting 2017, 阿德萊德, 澳大利亞
